Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2000

View Archived Issues

Company Profile: Pharmasset

AVI BioPharma's oral Resten-NG enters phase I testing

Cimetidine as treatment for viral warts in children and adults

E-5842: a new antipsychotic agent with anxiolytic-like properties

Functional dopamine-antagonist activity reported for SR-142801, an NK3 antagonist

Celecoxib in familial adenomatous polyposis

Licensing opportunity from NIH: treating renal cell carcinoma with FGF-5

Cancer chemoresistance may be weakened by inhibitors of fibroblast growth factors

Visudyne approved in E.U. for treatment of wet AMD

Rapamune regulatory application receives negative opinion from CPMP

Egis reports advances in preclinical and clinical programs

Proposed merger of Glaxo Wellcome and SmithKline Beecham advances on schedule

Hemosol seeks approval of Hemolink in Canada

Millennium and Aventis initiate major strategic alliance

Three-way merger to form Curis approved

Oxigene completes phase I trials of declopramide

Proneuron initiates phase I trial in spinal cord injury

Growth protein linked to the learning process

Synthesis, activity and use of NK1/NK2 receptor antagonists reported by AstraZeneca

New Roche compounds inhibit amidolytic activity of factor VIIa/tissue factor complex

TPO mimetics identified as part of joint SB/Ligand program

Antisense compounds from Isis modulate the expression of Akt-1

AstraZeneca presents new compounds with antiischemic effects

Recently issued patent covers B-I's new heterocyclic PDE4 inhibitors

Research at AHP leads to identification of novel 5-HT2C agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 9, 2025.
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Omada, Caris arrivals continue med-tech IPO hot streak
BioWorld MedTech
Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...